In GLI Pricing & Reimbursement, Attorneys Analyze Market Access to Medical Innovations and Relevance of International Drug Pricing

In The News
August 18, 2021

Scientific breakthroughs and technology advances have led to more precise medical treatments that are customized for the individual patient. But payers and policymakers increasingly are objecting to rising healthcare costs, which has resulted in many innovative treatments not being adopted for clinical application to benefit patients. 

In reflecting on the drug pricing legal and policy debates unfolding in various global jurisdictions, the following themes emerge: strong, and growing, interest in value-based pricing; governments’ increasingly active role in scrutinizing drug pricing; and the movement towards international reference prices for drugs. 

These topics are addressed in a Global Legal Insights - Pricing & Reimbursement 2021 chapter authored by life sciences regulatory & compliance partner Lincoln Tsang (London), head of the firm’s European Life Sciences practice, health care partner Margaux Hall (Washington, D.C.) and life sciences regulatory & compliance associate Hannah Kerr-Peterson (London).